Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–50 of 447 results
Advanced filters: Author: Michael Eisenstein Clear advanced filters

  • Nature Biotechnology’s annual survey highlights university startups that are, among other things, rethinking how to deliver gene-editing therapy and tackling various metabolic conditions, immune disorders and cancer with microbiome treatments or immunotherapy. Michael Eisenstein, Ken Garber, Esther Landhuis, Caroline Seydel and Laura DeFrancesco report.

    • Michael Eisenstein
    • Ken Garber
    • Laura DeFrancesco
    News
    Nature Biotechnology
    Volume: 39, P: 1036-1047

  • Scientists are pursuing sustainability strategies for intensifying production to tackle food security and environmental crises.

    • Michael Eisenstein
    Comments & Opinion
    Nature
    Volume: 588, P: S58-S59

  • Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report.

    • Michael Eisenstein
    • Ken Garber
    • Laura DeFrancesco
    Special Features
    Nature Biotechnology
    Volume: 38, P: 546-554

  • Cutting-edge materials and thoughtful urban planning can help cities beat the negative heating effects of climate change.

    • Michael Eisenstein
    Comments & Opinion
    Nature
    Volume: 648, P: S2-S4

  • Spectroscopy from the JWST Advanced Deep Extragalactic Survey of a galaxy at redshift 13 shows a singular, bright emission line identified as Lyman-α, suggesting the onset of reionization only 330 Myr after the Big Bang.

    • Joris Witstok
    • Peter Jakobsen
    • Yongda Zhu
    ResearchOpen Access
    Nature
    Volume: 639, P: 897-901

  • Nature Biotechnology’s annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets.

    • Michael Eisenstein
    • Charles Schmidt
    • Laura DeFrancesco
    News
    Nature Biotechnology
    Volume: 41, P: 1669-1678

  • DNA sequencing is helping clinicians to unravel the underpinnings of disease in individual patients.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 562, P: 291-293

  • Nature Biotechnology’s annual survey highlights academic startups that are, among other things, designing circular RNA therapeutics, tackling cancer with arenaviruses, creating psychedelics without the trip, editing genes and cells in vivo, harnessing the power of autoantibodies and editing the epigenome.

    • Michael Eisenstein
    • Ken Garber
    • Laura DeFrancesco
    News
    Nature Biotechnology
    Volume: 40, P: 1551-1562

  • Analysis of the JWST/NIRSpec spectrum of the recently observed Lyman-break galaxy JADES-GS+53.15508-27.80178 revealed a redshift of z = 7.3, a Balmer break and a complete absence of nebular emission lines, indicating that quenching occurred only 700 million years after the Big Bang.

    • Tobias J. Looser
    • Francesco D’Eugenio
    • Jan Scholtz
    ResearchOpen Access
    Nature
    Volume: 629, P: 53-57

  • Light microscopy is undergoing a renaissance, with a huge range of tools and techniques for gathering biological data with unprecedented speed and resolution. Michael Eisenstein takes a closer look.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 443, P: 1017-1019

  • With the patents on many biological drugs soon to expire, the biosimilars revolution is about to shift into top gear.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 569, P: S1

  • Protein microarrays are coming of age, and the development of specialized technologies is extending their high-throughput capabilities. Michael Eisenstein reports.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 444, P: 959

  • An extensive analysis of the JWST-NIRSpec spectrum of GN-z11 shows a supermassive black hole of a few million solar masses in a galaxy 440 million years after the Big Bang.

    • Roberto Maiolino
    • Jan Scholtz
    • Fengwu Sun
    ResearchOpen Access
    Nature
    Volume: 627, P: 59-63

  • Recent advances in cryo-electron microscopy are enabling researchers to solve protein structures at near-atomic resolutions, expanding the biological applicability of this technique. Michael Eisenstein reports.

    • Michael Eisenstein
    News
    Nature Methods
    Volume: 13, P: 19-22

  • Time-resolved cryo-electron microscopy can resolve protein motion on millisecond or even microsecond timescales, but the need for highly specialized tools and skills limits the method’s reach.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 642, P: 827-829

  • The quest to understand lysosomal storage disorders (LSDs) has left researchers grappling with questions that have implications for other diseases too.

    • Michael Eisenstein
    Comments & Opinion
    Nature
    Volume: 537, P: S165

  • The suggestion that pathogens play a part in driving dementia is not as niche as it once was, but the evidence remains inconclusive.

    • Michael Eisenstein
    Comments & Opinion
    Nature
    Volume: 640, P: S8-S10

  • Nature’s pick of tools and techniques that are poised to have an outsized impact on science in the coming year.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 613, P: 794-797

  • Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Enlaza Therapeutics is developing protein-based therapeutics that bind irreversibly to their target.

    • Michael Eisenstein
    News
    Nature Biotechnology
    Volume: 43, P: 1591-1592

  • One-size-fits-all intravenous delivery of biologics may be giving way to alternate delivery routes that enable safer and more efficient drug administration. Michael Eisenstein reports.

    • Michael Eisenstein
    News
    Nature Biotechnology
    Volume: 29, P: 107-109

  • Automating the microscopy and imaging process simplifies the testing of large numbers of compounds or growth conditions, and the subsequent monitoring of many different phenotypic indicators, giving researchers the power to dramatically scale up their cell-based assays. Caitlin Smith and Michael Eisenstein report.

    • Caitlin Smith
    • Michael Eisenstein
    Special Features
    Nature Methods
    Volume: 2, P: 547-555

  • The symptoms of Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease (IBD), can be severe and lifelong. And the condition is becoming increasingly common worldwide.

    • Michael Eisenstein
    Comments & Opinion
    Nature
    Volume: 540, P: S98-S99

  • Cancer blood tests and AI-powered scans look promising for quicker and more accurate detection of disease.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 640, P: S62-S64

    • Michael Eisenstein
    Research Highlights
    Nature Methods
    Volume: 2, P: 804

  • The gut is not the only part of the human body that hosts an important microbiome. The surface of the skin is home to a sprawling and complex microbial ecosystem, which interacts with the immune system and influences dermatological health.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 588, P: S210-S211

  • Methods for exploring the geography of molecular-scale processes within tissue samples are transforming cancer research, but the toolbox can be daunting.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 635, P: 1031-1033

  • Advances in artificial intelligence are at the heart of many of this year’s most exciting areas of technological innovation

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 625, P: 844-848

  • As issued patents on induced pluripotent stem (iPS) cells stack up, the specter of a patent thicket looms. Michael Eisenstein investigates.

    • Michael Eisenstein
    News
    Nature Biotechnology
    Volume: 28, P: 544-546

  • Doubt is often cast on the reliability of DNA microarrays, but resources are becoming available to help researchers overcome many of the problems inherent in this technology. Michael Eisenstein reports.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 442, P: 1069-1070

  • After a long lull, powerful new technologies are putting the charting of brain circuitry back on neuroscientists' agenda. Michael Eisenstein explores the challenge of mapping the mammalian mind.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 461, P: 1150-1152

  • A key element of performing good cell-biology experiments is starting with exactly the right cells. Michael Eisenstein takes a look at the technologies that can make this possible.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 441, P: 1179

  • Synthetic biologists have the know-how and ambition to retool whole genomes. But the hidden complexity of biological systems continues to surprise them.

    • Michael Eisenstein
    Special Features
    Nature
    Volume: 638, P: 848-850

    • Michael Eisenstein
    Research Highlights
    Nature Methods
    Volume: 2, P: 646

  • Coinciding with last month's annual meeting of the American Society of Clinical Oncology, at least one business launched with a plan to use genetic information from patient tumors to help guide treatment. Michael Eisenstein investigates.

    • Michael Eisenstein
    News
    Nature Biotechnology
    Volume: 30, P: 581-584